These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

609 related items for PubMed ID: 15792914

  • 21. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [Abstract] [Full Text] [Related]

  • 22. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J, Crouch T, McMurray S, Levine M, Prathikanti R, Scarlata D, Audhya P.
    Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
    [Abstract] [Full Text] [Related]

  • 23. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 24. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
    Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ.
    Nephrol Dial Transplant; 2004 Apr; 19(4):898-903. PubMed ID: 15031347
    [Abstract] [Full Text] [Related]

  • 25. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
    Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D.
    Oncologist; 2005 Sep; 10(8):642-50. PubMed ID: 16177289
    [Abstract] [Full Text] [Related]

  • 26. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    20030125 Study Group TrialUniversity of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA. jglaspy@mednet.ucla.edu, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G.
    J Clin Oncol; 2006 May 20; 24(15):2290-7. PubMed ID: 16710026
    [Abstract] [Full Text] [Related]

  • 27. Effects of darbepoetin alfa administered every two weeks on hemoglobin and quality of life of patients receiving chemotherapy.
    Folloder J.
    Oncol Nurs Forum; 2005 Jan 19; 32(1):81-91. PubMed ID: 15660146
    [Abstract] [Full Text] [Related]

  • 28. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A.
    Anticancer Res; 2008 Jan 19; 28(3B):1767-71. PubMed ID: 18630457
    [Abstract] [Full Text] [Related]

  • 29. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J.
    Nephrol Dial Transplant; 2003 Feb 19; 18(2):362-9. PubMed ID: 12543893
    [Abstract] [Full Text] [Related]

  • 30. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
    Vansteenkiste JF.
    Cancer Treat Rev; 2006 Feb 19; 32 Suppl 2():S11-5. PubMed ID: 16725268
    [Abstract] [Full Text] [Related]

  • 31. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L.
    Clin Breast Cancer; 2005 Dec 19; 6(5):446-54. PubMed ID: 16381629
    [Abstract] [Full Text] [Related]

  • 32. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA, Harpe SH, Brophy GM.
    Pharmacotherapy; 2007 Apr 19; 27(4):535-41. PubMed ID: 17381380
    [Abstract] [Full Text] [Related]

  • 33. Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency.
    Glaspy JA.
    Oncology (Williston Park); 2002 Sep 19; 16(9 Suppl 10):71-7. PubMed ID: 12380957
    [Abstract] [Full Text] [Related]

  • 34. Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting.
    Gascón P.
    Eur J Cancer; 2005 Nov 19; 41(17):2601-12. PubMed ID: 16230006
    [Abstract] [Full Text] [Related]

  • 35. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J.
    Oncologist; 2007 Oct 19; 12(10):1253-63. PubMed ID: 17962619
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naïve patients and patients switched from epoetin alfa.
    Thames WA, Smith SL, Scheifele AC, Yao B, Giffin SA, Alley JL.
    Pharmacotherapy; 2004 Mar 19; 24(3):313-23. PubMed ID: 15040644
    [Abstract] [Full Text] [Related]

  • 37. Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option.
    Cornes P, Coiffier B, Zambrowski JJ.
    Curr Med Res Opin; 2007 Feb 19; 23(2):357-68. PubMed ID: 17288690
    [Abstract] [Full Text] [Related]

  • 38. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
    Gordon D, Nichols G, Ben-Jacob A, Tomita D, Lillie T, Miller C.
    Oncologist; 2008 Jun 19; 13(6):715-24. PubMed ID: 18586927
    [Abstract] [Full Text] [Related]

  • 39. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
    Prescrire Int; 2005 Oct 19; 14(79):174-6. PubMed ID: 16285072
    [Abstract] [Full Text] [Related]

  • 40. Effects of aerobic exercise training in anemic cancer patients receiving darbepoetin alfa: a randomized controlled trial.
    Courneya KS, Jones LW, Peddle CJ, Sellar CM, Reiman T, Joy AA, Chua N, Tkachuk L, Mackey JR.
    Oncologist; 2008 Sep 19; 13(9):1012-20. PubMed ID: 18779540
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.